Table 2.

Univariate and multivariate survival analyses for OS

Variables		All patients (n = 447)	Univariate		Multivariate (model #1)		Multivariate (model #2)
			5-year OS (%)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Age, years	< 65	184	86.9	0.262
	> 65	263	82.9
Sex	Male	289	84.9	0.846
	Female	158	84.0
BMI, kg/m2	< 25	353	84.3	0.701
	> 25	94	85.7
PS	1	233	89.4	0.004*	1 1.16 (0.66–2.06)	0.601	1 1.06 (0.61–1.86)	0.837
	> 2	214	78.8
Hypertension	Presence	114	76.2	< 0.001*	1.50 (0.85–2.58) 1	0.158	1.50 (0.87–2.54) 1	0.147
	Absence	333	87.4
Diabetes mellitus	Presence	64	79.5	0.177
	Absence	383	85.4
Heart disease	Presence	50	70.0	< 0.001*	2.52 (1.22–4.99) 1	0.014*	2.14 (1.07–4.07) 1	0.033*
	Absence	397	86.4
Chronic renal failure	Presence	10	77.1	0.384
	Absence	437	84.8
Tumor location	Upper	145	75.5	< 0.001*	1.60 (0.93–2.71) 1	0.086	1.53 (0.90–2.58) 1	0.117
	Middle/lower	302	88.7
CEA, ng/ml	< 5	390	86.1	0.008*	1 1.51 (0.74–2.85)	0.243	1 1.68 (0.83–3.15)	0.143
	≥ 5	57	72.4
CA19-9, U/ml	< 37	422	85.7	0.003*	1 1.64 (0.77–3.90)	0.206	1 1.46 (0.70–3.42)	0.328
	≥ 37	25	65.3
Albumin, g/dl	< 3.5	19	44.2	< 0.001*	1.11 (0.45–2.92) 1	0.827	1.07 (0.40–2.31) 1	0.872
	≥ 3.5	428	86.4
CRP, mg/dl	< 0.5	397	87.0	< 0.001*	1 2.51 (1.16–5.16)	0.021*	1 2.45 (1.15–4.94)	0.021*
	≥ 0.5	50	65.5
Neutrophil count, cell/mm3	< 3690	223	88.9	0.020*	1 1.97 (1.08–3.68)	0.027*		NA
	≥ 3690	224	80.3
Lymphocyte count, cell/mm3	≥ 1860	200	89.3	0.011*	1 1.41 (0.80–2.56)	0.242		NA
	< 1860	247	80.6
Monocyte count, cell/mm3	< 320	194	87.4	0.198
	≥ 320	253	82.4
Platelet count, cell/mm3 × 104	< 27.2	338	87.6	0.003*	1 1.25 (0.65–2.34)	0.494		NA
	≥ 27.2	109	75.2
SII	< 395	167	92.7	< 0.001*		NA	1 2.95 (1.49–6.39)	0.001*
	≥ 395	280	80.0
pT	pT1-3	399	93.8	< 0.001*	1 3.99 (2.17–7.35)	< 0.001*	1 4.46 (2.44–8.14)	< 0.001*
	pT4	48	57.8
pN	pN0	323	93.7	< 0.001*	1 3.93 (2.01–7.95)	< 0.001*	1 4.02 (2.10–7.93)	< 0.001*
	pN+	124	60.8
Lymphatic invasion	Presence	169	71.3	< 0.001*	1.35 (0.69–2.68) 1	0.386	1.18 (0.61–2.32) 1	0.626
	Absence	278	92.7
Venous invasion	Presence	138	71.2	< 0.001*	1.13 (0.65–1.97) 1	0.675	1.22 (0.70–2.14) 1	0.475
	Absence	309	90.3
Tumor differentiation	Differentiated	231	87.3	0.148
	Undifferentiated	216	81.8

OS overall survival, BMI body mass index, PS physical status, CEA carcinoembryonic antigen, CA19-9 cancer antigen 19-9, CRP C-reactive protein, SII systemic immune inflammation index, HR hazard ratio, CI confidence interval, NA not applicable

^*p < 0.05 (significantly different between two groups)